Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Apr 12

PMID 35408980

Authors

Stavros P Papadakos

Nikolaos Dedes

Alexandros Pergaris

Maria Gazouli

Stamatios Theocharis

Affiliations

Soon will be listed here.

Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) constitutes a leading cause of cancer death globally. Its mortality remains unaltered despite the considerable scientific progress made in the fields of diagnostics and treatment. Exosomes comprise of small extracellular vesicles secreted by nearly all cells; their cargo contains a vast array of biomolecules, such as proteins and microRNAs. It is currently established that their role as messengers is central to a plethora of both physiologic and pathologic processes. Accumulating data have shed light on their contributions to carcinogenesis, metastasis, and immunological response. Meanwhile, the advancement of personalized targeted therapies into everyday clinical practice necessitates the development of cost-efficient treatment approaches. The role of exosomes is currently being extensively investigated towards this direction. This review aims to summarize the current pre-clinical and clinical evidence regarding the effects of exosomal applications in the timely diagnosis, prognosis, and therapeutic management of pancreatic cancer.

Citing Articles

Hydrogel models of pancreatic adenocarcinoma to study cell mechanosensing.

Walker M, Morton J Biophys Rev. 2025; 16(6):851-870.

PMID: 39830124 PMC: 11735828. DOI: 10.1007/s12551-024-01265-8.

Potential clinical applications of extracellular vesicles in pancreatic cancer: exploring untapped opportunities from biomarkers to novel therapeutic approaches.

Sanchez-Manas J, Perez de Gracia N, Perales S, Martinez-Galan J, Torres C, Real P Extracell Vesicles Circ Nucl Acids. 2024; 5(2):180-200.

PMID: 39698536 PMC: 11648502. DOI: 10.20517/evcna.2023.68.

Exosome applications for the diagnosis and treatment of pancreatic ductal adenocarcinoma: An update (Review).

Luan X, Wang X, Bian G, Li X, Gao Z, Liu Z Oncol Rep. 2024; 53(1).

PMID: 39575479 PMC: 11605277. DOI: 10.3892/or.2024.8846.

Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy.

Zhang S, Peng L, Chen Y, Xu Y, Moradi V Inflamm Regen. 2024; 44(1):45.

PMID: 39490997 PMC: 11533312. DOI: 10.1186/s41232-024-00358-x.

Targeting Neoantigens in Pancreatic Ductal Adenocarcinoma.

Singh G, Kutcher D, Lally R, Rai V Cancers (Basel). 2024; 16(11).

PMID: 38893220 PMC: 11171042. DOI: 10.3390/cancers16112101.

References

Xie Z, Gao Y, Ho C, Li L, Jin C, Wang X . Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment. Gut. 2021; 71(3):568-579. DOI: 10.1136/gutjnl-2020-323014. View

Wang W, Yue C, Gao S, Li S, Zhou J, Chen J . Promising Roles of Exosomal microRNAs in Systemic Lupus Erythematosus. Front Immunol. 2021; 12:757096. PMC: 8710456. DOI: 10.3389/fimmu.2021.757096. View

Wang R, Chen J, Wang W, Zhao Z, Wang H, Liu S . CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model. J Immunother Cancer. 2022; 10(1). PMC: 8796271. DOI: 10.1136/jitc-2021-003809. View

Mendt M, Kamerkar S, Sugimoto H, McAndrews K, Wu C, Gagea M . Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 2018; 3(8). PMC: 5931131. DOI: 10.1172/jci.insight.99263. View

Iodice S, Gandini S, Maisonneuve P, Lowenfels A . Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008; 393(4):535-45. DOI: 10.1007/s00423-007-0266-2. View

Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q . Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2020; 268:120546. DOI: 10.1016/j.biomaterials.2020.120546. View

Xiao L, Erb U, Zhao K, Hackert T, Zoller M . Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. Oncoimmunology. 2017; 6(6):e1319044. PMC: 5486185. DOI: 10.1080/2162402X.2017.1319044. View

Ryan D, Hong T, Bardeesy N . Pancreatic adenocarcinoma. N Engl J Med. 2014; 371(11):1039-49. DOI: 10.1056/NEJMra1404198. View

Sharma A . Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. Nanomedicine (Lond). 2017; 12(17):2137-2148. DOI: 10.2217/nnm-2017-0184. View

10.

Chu G, Kimmelman A, Hezel A, DePinho R . Stromal biology of pancreatic cancer. J Cell Biochem. 2007; 101(4):887-907. DOI: 10.1002/jcb.21209. View

11.

Jiang H, Courau T, Borison J, Ritchie A, Mayer A, Krummel M . Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism. Gastroenterology. 2021; 162(2):590-603.e14. DOI: 10.1053/j.gastro.2021.09.066. View

12.

Richards K, Zeleniak A, Fishel M, Wu J, Littlepage L, Hill R . Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. 2016; 36(13):1770-1778. PMC: 5366272. DOI: 10.1038/onc.2016.353. View

13.

Yu Z, Zhao S, Ren L, Wang L, Chen Z, Hoffman R . Pancreatic cancer-derived exosomes promote tumor metastasis and liver pre-metastatic niche formation. Oncotarget. 2017; 8(38):63461-63483. PMC: 5609937. DOI: 10.18632/oncotarget.18831. View

14.

Zhou Y, Zhou W, Chen X, Wang Q, Li C, Chen Q . Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer. Acta Pharm Sin B. 2020; 10(8):1563-1575. PMC: 7488356. DOI: 10.1016/j.apsb.2019.11.013. View

15.

Jiang L, Gu Y, Du Y, Liu J . Exosomes: Diagnostic Biomarkers and Therapeutic Delivery Vehicles for Cancer. Mol Pharm. 2019; 16(8):3333-3349. DOI: 10.1021/acs.molpharmaceut.9b00409. View

16.

Georgantzoglou N, Pergaris A, Masaoutis C, Theocharis S . Extracellular Vesicles as Biomarkers Carriers in Bladder Cancer: Diagnosis, Surveillance, and Treatment. Int J Mol Sci. 2021; 22(5). PMC: 7963171. DOI: 10.3390/ijms22052744. View

17.

Becker A, Hernandez Y, Frucht H, Lucas A . Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol. 2014; 20(32):11182-98. PMC: 4145757. DOI: 10.3748/wjg.v20.i32.11182. View

18.

Comandatore A, Immordino B, Balsano R, Capula M, Garajova I, Ciccolini J . Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer. Diagnostics (Basel). 2022; 12(2). PMC: 8871170. DOI: 10.3390/diagnostics12020286. View

19.

Zhao J, Schlosser H, Wang Z, Qin J, Li J, Popp F . Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. Cancers (Basel). 2019; 11(6). PMC: 6628179. DOI: 10.3390/cancers11060874. View

20.

Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R . Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol. 2007; 37(1):147-60. DOI: 10.1093/ije/dym219. View